The CEO of ARK Invest Management, Cathy Wood, is a controversial figure.
The money on the stock exchange (ETFS) that has struck gold several times by investing early in innovative and sabotage projects-with Tesla (Nasdaq: TSLA) is the main example.
The pioneering producer of Wood-Ark Innovation ETF (Arkk) was the best investment box in the world in 2020. However, it failed to repeat its previous success. At the time of the press on February 6, ARKK was traded at $ 63.81 – after gathering at 11.75 % since the beginning of 2025.
Since December, Wood has shown a clear style of selling technology stocks well and redirecting money to other assets. With high interest rates and the decrease in the possibilities of multiple price discounts, technical stocks, with assessments at standard levels, are risky assets. Most likely, the box closes its gains to mobilize them in a less dangerous way.
Palantir (NASDAQ: PLTR) was one of the best performances in modern memory, which is the latest element in the Cathy Wood-Wood cutting block, at the same time, its location rose in two potential biotechnology stocks.
Cathy Wood continues a fixed reduction of Palantir Stake
Palantir issued a fourth -quarter profit report on February 3. Data analysis business recorded a double victory – both profits for the share (EPS) and the revenues came in the forecasts of the above analysts. In addition, the administration provided the bullish guidance.
Palantir stock increased by 24 % to reach its highest levels (ATH) of $ 106 on February 4. By the time of the press on February 6, the prices fell – PLTR shares were changing for $ 100.72.
Despite these successes, the company’s high evaluation is a point of disagreement. In late November 2024, Cathy Wood sold nearly $ 1.7 million of PLTR shares – and followed by selling the largest $ 17 million in early January.
Recently, ARKK 71,069 Palantir has sold on February 4. While we are not familiar with the exact prices that have been made in transactions, we can soften education. Since PLTR shares traded between $ 101.68 and $ 106, the use of the medium point of $ 103.84 brings the value of the sale to up to 7,379,804 dollars.
ARKK increases the parking for biotechnology stocks
In contrast to the sale of PLTR, the Wood Fund has increased its share in 3 biotechnology companies – Illumina Inc (Nasdaq: ILMN), 10x Genomics Inc (Nasdaq: TXG), and Twist Bioscience Corp (Nasdaq Twst).
The acquisitions are more important because biotechnology is usually another area of ARK – Jinnom Revolution Ark Etf (Arkg). All in all, the acquisitions cost a total of 9,145,824 dollars – 6.7 million dollars from that went to ILMN shares, $ 1.46 million was used to buy TXG shares, and more than $ 960,000 was used to buy biology shares.
Of the three, the TWST stocks are only in green compared to this time last year and on the basis of the year (YTD). However, analysts only predict an average rise in Twist Bioscience shares – while they are completely optimistic about TXG and ILMN.
ILLUMINA Inc. Chamber call calls Today, on February 6, after the market was closed. 10x gyneum reporting profits On February 12. Investors who are looking for a better overview of the latest Wood Blins in Biotechnology should closely monitor results, as well as price movement in the wake of direct issues.
Slip: The distinctive image in this article is for illustrative purposes only and may not accurately reflect the true similarity of photographers.
